SIGA - SIGA Technologies, Inc.
| Previous Close | 5.07 |
| Open | 5.11 |
| Bid | 5.14 x 1400 |
| Ask | 6.49 x 800 |
| Day's Range | 5.10 - 5.20 |
| 52 Week Range | 4.68 - 8.47 |
| Volume | 92,623 |
| Avg. Volume | 141,189 |
| Market Cap | 420.896M |
| Beta (3Y Monthly) | 0.99 |
| PE Ratio (TTM) | 0.99 |
| EPS (TTM) | 5.26 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
SIGA Awarded Department of Defense Contract to Develop Expanded Indication for TPOXX® as Post-Exposure Prophylactic for Smallpox
As previously announced, SIGA is already working with the U.S. Army Medical Research Institute of Infectious Disease on animal studies to evaluate the efficacy of TPOXX as a potential PEP therapy for smallpox. The use of TPOXX for PEP could provide significant potential benefit in the event of a smallpox outbreak. While vaccines would play an important role in containing the spread of smallpox, the vaccines are only effective if administered prior to infection or no later than four days after infection.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On SIGA Technologies Inc. (SIGA)
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
- GlobeNewswire
SIGA Technologies CEO to Speak at NCT Europe on June 27, 2019
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats (NCT) Europe Conference in Vienna, Austria. Dr. Gomez will present on “Medical Preparedness for Chemical, Biological, Radiological and Nuclear Defense (CBRNe) Incidents” at 8:30 A.M. Central European Summer Time on Thursday, June 27, 2019. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
- GlobeNewswire
SIGA Technologies to Host Business Update Webcast on June 18, 2019
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, June 18, 2019. Participants may also call (877) 407-6184 (United States/Canada) or (201) 389-0877 (International) and request the SIGA Technologies call or provide confirmation code 13691653. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
- GlobeNewswire
SIGA Announces TPOXX® Promotion Agreement with Meridian Medical Technologies, Inc. (A Pfizer Company) for International Markets
“Meridian, a leader within the global medical countermeasure industry, has sold products in over 30 countries worldwide and has been marketing and distributing emergency care treatment options to military and civilian authorities for more than 50 years.
- Insider Monkey
Oaktree Capital Management’s Latest Moves
Oaktree Capital Management is an alternative investment manager that was launched back in 1995 by a group of individuals who had been working together at TCW Group. Among them was Howard Marks, who is the fund’s current co-Chairman. Mr. Marks, a chartered financial analyst, earned a B.S.Ec. degree cum laude from the Wharton School of […]
- GlobeNewswire
SIGA Announces Exercise of Option for the Purchase of Raw Materials for Oral TPOXX® Manufacturing Totaling $11 Million
Raw Materials expected to be used to Support Manufacture of 363,070 Courses of Oral TPOXX NEW YORK, May 20, 2019 -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a.
GuruFocus.com6 Low Price-Earnings Stocks
With a market cap of $ 728.29 million, Rite Aid Corp. (RAD) is trading with a price-earnings ratio of 0.39 and a price-book ratio of 0.49. The share price has fallen 55% over the last 12 months and is trading 68.19% below its 52-week high and 12.4% above its 52-week low. Warning! GuruFocus has detected 5 Warning Signs with RAD.
- GlobeNewswire
SIGA to Present at the 8th Annual SVB Leerink Global Healthcare Conference on March 1, 2019
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference at 9:00 am ET on Friday, March 1, 2019 in New York. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
- GlobeNewswire
Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Insider Monkey
How Immersion Corporation (IMMR) Stacks Up Against Its Market Cap Peers
Is Immersion Corporation (NASDAQ:IMMR) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
- GlobeNewswire
SIGA Announces Priority Review Voucher Transaction Totaling $80 Million
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an agreement to sell its medical countermeasures priority review voucher (PRV) for a lump sum payment of $80 million. SIGA was awarded the PRV in July 2018 upon approval by the U.S. Food and Drug Administration (FDA) of oral TPOXX® for the treatment of smallpox. The PRV was awarded by FDA under a provision that encourages development of medical countermeasures enacted as part of the 21st Century Cures Act (Public Law 114-255).
